Parametric Portfolio Associates’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $5.15M | Buy |
81,488
+17,441
| +27% | +$948K | ﹤0.01% | 1836 |
|
|
2021
Q4 | $3.4M | Sell |
64,047
-113,868
| -64% | -$6.94M | ﹤0.01% | 2115 |
|
|
2021
Q3 | $12.6M | Buy |
177,915
+58,572
| +49% | +$3.7M | 0.01% | 1207 |
|
|
2021
Q2 | $7.95M | Buy |
119,343
+21,103
| +21% | +$1.49M | ﹤0.01% | 1550 |
|
|
2021
Q1 | $10.9M | Sell |
98,240
-2,114
| -2% | -$262K | 0.01% | 1605 |
|
|
2020
Q4 | $11.9M | Buy |
100,354
+930
| +0.9% | +$100K | 0.01% | 1434 |
|
|
2020
Q3 | $8.68M | Buy |
99,424
+564
| +0.6% | +$49.3K | 0.01% | 1490 |
|
|
2020
Q2 | $8.85M | Sell |
98,860
-23,981
| -20% | -$2.42M | 0.01% | 1480 |
|
|
2020
Q1 | $12.2M | Buy |
122,841
+12,831
| +12% | +$1.39M | 0.01% | 1087 |
|
|
2019
Q4 | $12.6M | Sell |
110,010
-10,881
| -9% | -$1.32M | 0.01% | 1322 |
|
|
2019
Q3 | $15.2M | Buy |
120,891
+8,929
| +8% | +$1.13M | 0.01% | 1116 |
|
|
2019
Q2 | $13.5M | Sell |
111,962
-21,958
| -16% | -$2.16M | 0.01% | 1216 |
|
|
2019
Q1 | $11.7M | Sell |
133,920
-62,904
| -32% | -$5.72M | 0.01% | 1314 |
|
|
2018
Q4 | $19.7M | Sell |
196,824
-19,321
| -9% | -$2.03M | 0.02% | 819 |
|
|
2018
Q3 | $24.8M | Sell |
216,145
-17,889
| -8% | -$1.85M | 0.02% | 759 |
|
|
2018
Q2 | $21M | Buy |
234,034
+33,999
| +17% | +$2.87M | 0.02% | 812 |
|
|
2018
Q1 | $14.6M | Buy |
200,035
+26,581
| +15% | +$1.82M | 0.01% | 1034 |
|
|
2017
Q4 | $10.1M | Buy |
173,454
+88,579
| +104% | +$4.66M | 0.01% | 1327 |
|
|
2017
Q3 | $3.81M | Buy |
84,875
+4,603
| +6% | +$191K | ﹤0.01% | 2090 |
|
|
2017
Q2 | $3.17M | Sell |
80,272
-224,827
| -74% | -$9.23M | ﹤0.01% | 2162 |
|
|
2017
Q1 | $12.4M | Buy |
305,099
+230,514
| +309% | +$9M | 0.02% | 966 |
|
|
2016
Q4 | $3M | Sell |
74,585
-215,384
| -74% | -$8.12M | ﹤0.01% | 2089 |
|
|
2016
Q3 | $10.5M | Buy |
289,969
+106,143
| +58% | +$3.64M | 0.02% | 929 |
|
|
2016
Q2 | $5.33M | Sell |
183,826
-26,930
| -13% | -$814K | 0.01% | 1472 |
|
|
2016
Q1 | $7.37M | Buy |
210,756
+13,369
| +7% | +$432K | 0.01% | 1178 |
|
|
2015
Q4 | $6.36M | Buy |
197,387
+115,188
| +140% | +$3.74M | 0.01% | 1153 |
|
|
2015
Q3 | $2.66M | Sell |
82,199
-1,333
| -2% | -$50.2K | 0.01% | 1624 |
|
|
2015
Q2 | $3.46M | Buy |
83,532
+3,071
| +4% | +$129K | 0.01% | 1725 |
|
|
2015
Q1 | $3.61M | Buy |
80,461
+13,082
| +19% | +$547K | 0.01% | 1646 |
|
|
2014
Q4 | $2.52M | Buy |
67,379
+429
| +0.6% | +$15.7K | 0.01% | 1953 |
|
|
2014
Q3 | $2.34M | Buy |
66,950
+14,316
| +27% | +$511K | 0.01% | 1926 |
|
|
2014
Q2 | $1.86M | Buy |
52,634
+16,681
| +46% | +$557K | ﹤0.01% | 2156 |
|
|
2014
Q1 | $1.17M | Buy |
35,953
+1,969
| +6% | +$75.3K | ﹤0.01% | 2548 |
|
|
2013
Q4 | $1.43M | Buy |
33,984
+157
| +0.5% | +$6.46K | ﹤0.01% | 2350 |
|
|
2013
Q3 | $1.35M | Sell |
33,827
-425
| -1% | -$17.8K | ﹤0.01% | 2301 |
|
|
2013
Q2 | $1.42M | Buy |
+34,252
| New | +$1.39M | ﹤0.01% | 2137 |
|
Other funds holding HAE
LCOV
LCP
Parametric Portfolio Associates's HAE Position: Q1 2022 in Review
Parametric Portfolio Associates increased its Haemonetics (HAE) stake by 27% in Q1 2022, buying an estimated $948K and bringing the position to 81,488 shares worth $5.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1836.
Parametric Portfolio Associates first reported a position in HAE in Q2 2013 and has held it in 36 quarters since. The position peaked at $24.8M in Q3 2018. 242 funds tracked by Wall St. Rank hold HAE as of Q1 2022.
- Parametric Portfolio Associates held 81,488 shares of Haemonetics worth $5.15M as of Q1 2022.
- Parametric Portfolio Associates bought 17,441 Haemonetics shares in Q1 2022, an estimated $948K.
- Haemonetics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1836 holding.
- Parametric Portfolio Associates first reported a position in Haemonetics in Q2 2013 and has held it in 36 quarters since.
- Parametric Portfolio Associates's Haemonetics position peaked at $24.8M in Q3 2018.
- 242 funds tracked by Wall St. Rank held Haemonetics as of Q1 2022.
Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.